Pursuant to Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sword & Shield Pharma has informed that the Board of Directors of the Company in their meeting held on Wednesday, 13th June, 2018 have authorized one or more KMPs for the purpose of determining materiality of an event and for the purpose of making disclosures to the Stock Exchange, in terms of Policy adopted by the Board.
The above information is a part of company’s filings submitted to BSE.
